Literature DB >> 3562057

The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis.

R A De Rossell, R S Bray, J Alexander.   

Abstract

The growth of Leishmania major and Leishmania mexicana lesions and the concomitant development of delayed-type hypersensitivity (DTH) to homologous or heterologous soluble antigen was studied in BALB/c and CBA/Ca mice. Although CBA/Ca mice are highly susceptible to L. mexicana, developing non-healing lesions, they are resistant to L. major; while BALB/c mice develop non-healing lesions when infected with either species. The development of resistance was associated with the acquisition of DTH which peaked at 48 h (L. major infected CBA/Ca mice). Non healing lesions were associated with either negative DTH (L. major infected BALB/c mice) or DTH that peaked at 24 h but had significantly subsided by 48 h (L. mexicana infected CBA/Ca and BALB/c mice). The latter response was associated with basophilic infiltration of the skin test site. Pre-irradiating (600 rad) CBA/Ca and BALB/c mice induced resistance against L. mexicana and L. major respectively in conjunction with the appearance of 48 h DTH to the homologous antigen. There was clear dissociation in the skin reactivity produced by the heterologous antigen. Thus L. major-derived antigen failed to produce DTH in L. mexicana infected mice of either strain. L. mexicana-derived antigen on the other hand produced a quicker response and of greater magnitude than the homologous antigen in L. major infected CBA/Ca mice. This correlated well with the strong cross-immunity induced by L. major in these mice to L. mexicana infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3562057     DOI: 10.1111/j.1365-3024.1987.tb00492.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  8 in total

1.  New Zealand black mice are immunologically resistant to high-dose, but not low-dose Leishmania mexicana infection.

Authors:  R C Dorea; J Alexander; G Gallagher
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

2.  Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis.

Authors:  F Y Liew; S Millott; R Lelchuk; S Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

3.  Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.

Authors:  M M Gicheru; J O Olobo; C O Anjili; A S Orago; F Modabber; P Scott
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Evidence of T-cell recognition in mice of a purified lipophosphoglycan from Leishmania major.

Authors:  H Moll; G F Mitchell; M J McConville; E Handman
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

5.  Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice.

Authors:  Hamid Mahmoudzadeh-Niknam; Simin Sadat Kiaei; Davood Iravani
Journal:  Korean J Parasitol       Date:  2007-06       Impact factor: 1.341

6.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

7.  Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis.

Authors:  Meenakshi Sharma; Rakesh Sehgal; Sukhbir Kaur
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01

8.  Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice.

Authors:  Mosayeb Rostamian; Fariborz Bahrami; Hamid M Niknam
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.